We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Microfluidic Device Created For Genetic Analysis

By LabMedica International staff writers
Posted on 17 Aug 2011
A silicone chip based apparatus has been generated that could make genetic analysis far more sensitive, rapid, and cost-effective. More...


The device, which is about the size of a nine-volt battery, allows simultaneously analysis of 300 individual cells by routing fluid carrying cells through microscopic tubes and valves.

Scientists at the University of British Columbia, (UBC; Vancouver, BC, Canada) isolated the cells into their separate chambers, and then extracted and replicated the cells' ribonucleic acid (RNA) for further analysis. The device's ease of use and cost-effectiveness arise from its integration of almost the entire process of cell analysis, not just separating the cells, but also mixing them with chemical reagents to highlight their genetic code and analyzing the results by measuring fluorescent light emitted from the reaction. All of that can now be done on the chip.

The fully integrated microfluidic device is capable of performing high-precision real-time quantitative polymerase chain reaction (RT-qPCR) measurements of gene expression from hundreds of single cells per run. The device executes all steps of single-cell processing, including cell capture, cell lysis, reverse transcription, and quantitative PCR. By enabling such "single-cell analysis," the device could accelerate genetic research and hasten the use of far more detailed tests for diagnosing cancer. The standard genetic tests, which require large numbers of cells, capture only an average composite picture of thousands or millions of different cells that may obscure their true nature and the interactions between them.

Carl Hansen, PhD, an assistant professor at UCB said, "This technology and other approaches like it could radically change the way we do both basic and applied biomedical research, and would make single-cell analysis a more plausible option for treating patients, allowing clinicians to distinguish various cancers from one another and tailor their treatments accordingly." The study was published August 1, 2011, in the Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Related Links:

University of British Columbia




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Turbidimetric Control
D-Dimer Turbidimetric Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.